<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11851">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539032</url>
  </required_header>
  <id_info>
    <org_study_id>MTA47</org_study_id>
    <nct_id>NCT00539032</nct_id>
  </id_info>
  <brief_title>Immunology and Safety of Menactra® in Children in Saudi Arabia</brief_title>
  <official_title>Evaluation of the Response to a Single Dose of Menactra® in Children Aged 5 to 8 Years Who Had Previously Received Two Doses of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide Vaccine Before Age 2 Years in Saudi Arabia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>Saudi Arabia: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted among children in Saudi Arabia who previously received two
      doses of A, C, Y, W-135 polysaccharide vaccine before the age of 2 years, and in
      meningococcal vaccine-naïve children (Control Group). This study will evaluate the
      administration of Menactra® in terms of the serum bactericidal antibody it induces in the
      two study groups. Safety of Menactra® vaccine will be described.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) as Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination.</measure>
    <time_frame>Day 0 (baseline or pre-vaccination) and Day 28 Post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With ≥ 4-Fold Rise in Titers for the Menactra® Vaccine Serogroups A, C, Y, and W-135.</measure>
    <time_frame>Day 28 Post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting At Least 1 Solicited Injection Site or Systemic Reaction Post-Vaccination With Menactra®</measure>
    <time_frame>Days 0-7 Post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited injection Site reactions: Pain, erythema, and swelling; Solicited systemic reactions: Fever, headache, malaise and myalgia.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcemia</condition>
  <arm_group>
    <arm_group_label>Group 1: Menactra® Booster Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Menactra® Primary Vaccine (Control) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1: Menactra® Booster Group</arm_group_label>
    <other_name>Menactra® Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2: Menactra® Primary Vaccine (Control) Group</arm_group_label>
    <other_name>Menactra® Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Healthy, as determined by medical history and physical examination.

          -  Aged between 5 to 8 years on the day of inclusion (from 5th birthday to 1 day before
             9th birthday inclusive).

          -  For the Booster Group , two doses of a quadrivalent (A, C, Y, W-135) meningococcal
             polysaccharide vaccine received before age 2 years

          -  For the Control Group , no previous history of any meningococcal vaccination

          -  Informed consent form signed by the parent(s) or other legal representative

          -  Able to provide a vaccination log or has available vaccination record in the Health
             Center.

          -  Able to attend all scheduled visits and to comply with all trial procedures

        Exclusion Criteria :

          -  Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic,
             psychiatric, etc.)

          -  Known or suspected impairment of immunologic function.

          -  Acute medical illness with or without fever within the last 72 hours or a oral
             temperature ≥ 37.5°C at the time of inclusion.

          -  Administration of immune globulin or other blood products within the last three
             months, injected or oral corticosteroids or other immunomodulatory therapy within six
             weeks of the trial vaccine. Individuals on a tapering dose schedule of oral steroids
             lasting &lt; 7 days may be included in the trial provided that they have not received
             more than one course within the last two weeks prior to enrollment.

          -  Oral or injected antibiotic therapy within the 72 hours prior to vaccination.

          -  Received any vaccine in the 14-day period prior to trial vaccination, or scheduled to
             receive any vaccination during the 14-day period after trial vaccination.

          -  Previous history of documented invasive meningococcal disease.

          -  For the Control Group, previous history of any meningococcal vaccination.

          -  Systemic hypersensitivity to any of the vaccines components or history of a
             life-threatening reaction to the trial vaccines or a vaccine containing the same
             substances.

          -  Participation in another clinical trial in the 4 weeks preceding the trial
             vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Any condition, which, in the opinion of the investigator, would pose a health risk to
             the subject, or interfere with the evaluation of the vaccine.

          -  Personal or family history of Guillain Barré syndrome.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>AlKhaleej</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>AlRabwa</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>S. Buraida</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safra-Al Midhnab</city>
        <state>Qassim</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 12, 2016</lastchanged_date>
  <firstreceived_date>October 2, 2007</firstreceived_date>
  <firstreceived_results_date>September 9, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N. meningitidis</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 30 September to 03 November 2007, at 4 health centers in Saudi Arabia.</recruitment_details>
      <pre_assignment_details>A total of 238 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Menactra® Booster Group</title>
          <description>Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Menactra® Primary Vaccine (Control) Group</title>
          <description>Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Menactra® Booster Group</title>
          <description>Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Menactra® Primary Vaccine (Control) Group</title>
          <description>Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="153"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="238"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="153"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="238"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6.12" spread="0.60"/>
                <measurement group_id="B2" value="6.52" spread="1.22"/>
                <measurement group_id="B3" value="6.26" spread="0.89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="131"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="107"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Saudi Arabia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="153"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="238"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting At Least 1 Solicited Injection Site or Systemic Reaction Post-Vaccination With Menactra®</title>
        <description>Solicited injection Site reactions: Pain, erythema, and swelling; Solicited systemic reactions: Fever, headache, malaise and myalgia.</description>
        <time_frame>Days 0-7 Post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® Booster Group</title>
            <description>Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® Primary Vaccine (Control) Group</title>
            <description>Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting At Least 1 Solicited Injection Site or Systemic Reaction Post-Vaccination With Menactra®</title>
            <description>Solicited injection Site reactions: Pain, erythema, and swelling; Solicited systemic reactions: Fever, headache, malaise and myalgia.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Solicited Injection Site Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Erythema (≥ 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling (≥ 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Solicited Systemic Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever (&gt; 39.0 ºC)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache (Prevents daily activities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Malaise (Prevents daily activities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia (Prevents daily activities)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) as Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination.</title>
        <time_frame>Day 0 (baseline or pre-vaccination) and Day 28 Post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Geometric mean titers by serum bactericidal assay were determined in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® Booster Group</title>
            <description>Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® Primary Vaccine (Control) Group</title>
            <description>Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) as Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination.</title>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A: Pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="168.9" lower_limit="117.4" upper_limit="243.1"/>
                  <measurement group_id="O2" value="196.4" lower_limit="119.0" upper_limit="324.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup A: Day 28 Post-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6991.7" lower_limit="6107.6" upper_limit="8003.8"/>
                  <measurement group_id="O2" value="8263.3" lower_limit="6913.1" upper_limit="9877.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C: Pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.5" lower_limit="2.2" upper_limit="3.0"/>
                  <measurement group_id="O2" value="4.1" lower_limit="2.8" upper_limit="5.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C: Day 28 Post-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="167.2" lower_limit="115.3" upper_limit="242.7"/>
                  <measurement group_id="O2" value="512.0" lower_limit="334.4" upper_limit="761.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y: Pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.2" lower_limit="6.8" upper_limit="15.2"/>
                  <measurement group_id="O2" value="12.4" lower_limit="7.1" upper_limit="21.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y: Day 28 Post-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2120.2" lower_limit="1799.0" upper_limit="2498.9"/>
                  <measurement group_id="O2" value="2558.3" lower_limit="2015.5" upper_limit="3247.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W-135: Pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="2.4" upper_limit="3.8"/>
                  <measurement group_id="O2" value="2.7" lower_limit="2.1" upper_limit="3.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W-135: Day 28 Post-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2387.7" lower_limit="1950.1" upper_limit="2923.5"/>
                  <measurement group_id="O2" value="2763.2" lower_limit="2153.9" upper_limit="3544.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With ≥ 4-Fold Rise in Titers for the Menactra® Vaccine Serogroups A, C, Y, and W-135.</title>
        <time_frame>Day 28 Post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>4-Fold rise in Menactra® vaccine antibodies were evaluated in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® Booster Group</title>
            <description>Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® Primary Vaccine (Control) Group</title>
            <description>Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With ≥ 4-Fold Rise in Titers for the Menactra® Vaccine Serogroups A, C, Y, and W-135.</title>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Serogroup A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="97"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W-135</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination for up to 28 days post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Menactra® Booster Group</title>
          <description>Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Menactra® Primary Vaccine (Control) Group</title>
          <description>Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Postoperative wound infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="151"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="151"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="151"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
